Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

graft-versus-host-disease

This page shows the latest graft-versus-host-disease news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s Imbruvica bags FDA approval for paediatric patients with chronic graft versus host disease

AbbVie’s Imbruvica bags FDA approval for paediatric patients with chronic graft versus host disease

AbbVie’s Imbruvica (ibrutinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of paediatric patients one year and older with chronic graft versus host disease ... Now, healthcare professionals have another effective

Latest news

  • Sanofi’s Rezurock results show positive patient outcomes Sanofi’s Rezurock results show positive patient outcomes

    Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes. ... Knowing the impact that chronic graft-versus-host disease has on patients, the results add support for use of

  • FDA approves first drug to prevent graft-versus-host disease FDA approves first drug to prevent graft-versus-host disease

    Yet, up to 70% of patients that receive stem cell transplants, especially those who receive them from an unrelated donor, are impacted by acute graft-versus-host disease (aGvHD), where the ... Acute graft-versus-host disease can affect different parts of

  • Novartis pulls out of Mesoblast deal Novartis pulls out of Mesoblast deal

    When it announced a deal with Australian inflammatory disease specialist Mesoblast back in November last year, Basel-based Novartis described its lead candidate, remestemcel-L, as ‘an important addition to our ... In another blow, a few weeks earlier,

  • Sanofi boosts transplant portfolio with newly approved Rezurock Sanofi boosts transplant portfolio with newly approved Rezurock

    graft-versus-host disease around the world.”. ... In July, the FDA approved Rezurock for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

  • FDA to consider BMS’ Orencia for graft versus host disease FDA to consider BMS’ Orencia for graft versus host disease

    The US Food and Drug Administration has accepted a supplemental biologics licence application for Bristol Myers Squibb’s Orencia (abatacept) for the prevention of moderate-to-severe acute graft versus host ... disease (aGvHD) in patients receiving a

More from news
Approximately 4 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... The latter cost anywhere between $500, 000 and $1m, while also carrying the risk of having to treat adverse events such as graft versus host disease, for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Quick links